Sutro Biopharma is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).
For the year ended December 31, 2025, the company reported total revenue of $102.5 million. The net loss per share, basic and diluted, was reported at $(22.49).
As of December 31, 2025, the company held $141.4 million in cash, cash equivalents, and marketable securities. Furthermore, an underwritten stock offering generated $110.0 million in gross proceeds.